Researchers from Memorial Sloan-Kettering Cancer Center Report Details of New Studies and Findings in the Area of Carcinomas (Pou2f3 In Sclc: Clinicopathologic and Genomic Analysis With a Focus On Its Diagnostic Utility In Neuroendocrine-low ...).

The news correspondents obtained a quote from the research from Memorial Sloan-Kettering Cancer Center, "We screened 254 SCLC for POU2F3 expression and comprehensively analyzed histopathologic, genomic, and clinical characteristics of POU2F3-positive tumors. This is the largest cohort of SCLC-P clinical samples to date, where we describe the diagnostic utility of POU2F3 in a challenging subset of SCLC with low or absent expression of standard neuroendocrine markers. Keywords: New York City; State:New York; United States; North and Central America; Biomarkers; Cancer; Carcinomas; Diagnostics and Screening; Genetics; Health and Medicine; Oncology EN New York City State:New York United States North and Central America Biomarkers Cancer Carcinomas Diagnostics and Screening Genetics Health and Medicine Oncology 2023 JAN 31 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- A new study on Oncology - Carcinomas is now available. [Extracted from the article]